We are live on ! Find out more
FBIOP icon

Fortress Biotech 9.375% Series A Preferred Stock
FBIOP

4 hedge funds and large institutions have $6.32M invested in Fortress Biotech 9.375% Series A Preferred Stock in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 3 → 4 (+1)

11% more capital invested

Capital invested by funds: $5.72M → $6.32M (+$602K)

0.47% more ownership

Funds ownership: 9.03% → 9.51% (+0.47%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
Bramshill Investments
Florida
+$628K
2
SAM
Shikiar Asset Management
New York
+$81.7K

Top Sellers

Rank Fund Capital Flow
1
UIC
Uniplan Investment Counsel
Wisconsin
-$285K
Name Holding Trade Value Shares
Change 		Change in
Stake
UIC
1
Uniplan Investment Counsel
Wisconsin
$3.56M -$285K -15,189 -8%
SAM
2
Shikiar Asset Management
New York
$2.11M +$81.7K +4,350 +4%
BI
3
Bramshill Investments
Florida
$648K +$628K +33,424 New
PCG
4
Private Capital Group
Connecticut
$3K – – –

FBIOP Hedge Fund Activity: Q4 2020 in Review

4 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) for Q4 2020, worth a combined $6.32M — up 11% from $5.72M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new FBIOP positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Bramshill Investments, opening a new position worth an estimated $628K. The largest seller was Uniplan Investment Counsel, cutting an estimated $285K.

  • 4 institutional investors held Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) as of Q4 2020, up from 3 in Q3 2020.
  • Funds reported $6.32M of Fortress Biotech 9.375% Series A Preferred Stock stock for Q4 2020, up 11% quarter-over-quarter.
  • 1 fund opened new Fortress Biotech 9.375% Series A Preferred Stock positions in Q4 2020 and 0 closed out, a net change of +1 holder.
  • The largest Fortress Biotech 9.375% Series A Preferred Stock buyer in Q4 2020 was Bramshill Investments, an estimated $628K added.
  • The largest Fortress Biotech 9.375% Series A Preferred Stock seller in Q4 2020 was Uniplan Investment Counsel, an estimated $285K sold.

Based on aggregated 13F filings for Q4 2020.